Xiaflex (collagenase clostridium histolyticum) / Asahi Kasei, SOBI, Endo - LARVOL DELTA

Trends in Medicare utilization of intralesional collagenase injection and surgery for Peyronie's disease, 2013-2023. (PubMed, J Sex Med) - No abstract available

Journal • Medicare • Reimbursement • US reimbursement

Digital Artery Pseudoaneurysm After Collagenase Injection for Dupuytren Contracture: A Case Report. (PubMed, Hand (N Y)) - "Collagenase Clostridium histolyticum (CCH; Xiaflex) is an established nonsurgical therapy for Dupuytren contracture...Digital artery pseudoaneurysm is a potential, previously unreported complication of CCH injection for Dupuytren contracture. New or pulsatile swelling after manipulation should prompt vascular imaging to exclude this diagnosis."

Journal • Cardiovascular

Safety and Efficacy of Collagenase Clostridium Histolyticum After Prior Intralesional PRP for Peyronie's Disease (clinicaltrials.gov) - P4 | N=22 | Recruiting | Sponsor: University of Miami | Trial completion date: Jan 2026 ➔ Jan 2027 | Trial primary completion date: Jan 2026 ➔ Jan 2027

Trial completion date • Trial primary completion date • Sexual Disorders

Likelihood of Dupuytren Contracture Recurrence After Limited Fasciectomy, Needle Aponeurotomy or Collagenase Clostridium histolyticum: Systematic Review of Prospective Data With 2- to 7-Year Follow-up. (PubMed, J Hand Surg Glob Online) - "LF offers greater durability and a lower likelihood of subsequent procedures than CCH or NA in the treatment of DC at intermediate term follow-up; however, the clinician must also weigh the length of recovery and potential complications between these three treatment options. Patients with PIP contractures should be counseled about a higher recurrence risk and potential need for closer follow-up."

Journal • Pain

STRIDE: Study to Assess EN3835 in the Treatment of Plantar Fibromatosis (Also Known as Ledderhose Disease) (clinicaltrials.gov) - P3 | N=418 | Active, not recruiting | Sponsor: Endo Pharmaceuticals | Recruiting ➔ Active, not recruiting

Enrollment closed • Fibrosis • Solid Tumor

Trends in Penile Fracture and Repair after Intralesional Collagenase Clostridium Histolyticum for Peyronie's Disease: An Analysis of the MarketScan Database 2014-2024 (AUA 2026) - No abstract available

Musculoskeletal Diseases

Delayed Dose Collagenase Clostridium Histolyticum Protocol for Men with Peyronie's Disease: A Prospective Clinical Study (AUA 2026) - No abstract available

Clinical

Efficacy of Collagenase Clostridium histolyticum in Active versus Stable Peyronie's Disease Phases (AUA 2026) - No abstract available

Clinical

Comparison of Collagenase Clostridium Histolyticum to Surgery for the Management of Peyronie's Disease: A Randomized Trial – 3 Year Outcomes (AUA 2026) - No abstract available

Clinical • Surgery

Final Results of a Multicenter, Retrospective Analysis of Collagenase Clostridium Histolyticum (CCH) for Ventral Penile Curvature in Peyronie's Disease (AUA 2026) - No abstract available

Retrospective data

Efficacy of a Novel Collagenase Clostridium Histolyticum Protocol for Peyronie's Disease Among Prior Non-responders: A Randomized, Controlled, Single-Blinded Study (AUA 2026) - No abstract available

Clinical

Impact of Testosterone on Treatment Outcomes in Peyronie's Disease: A Multicenter Retrospective Analysis of Collagenase Clostridium Histolyticum Therapy (AUA 2026) - No abstract available

Retrospective data

The Impact of Collagenase Clostridium Histolyticum (CCH) Priming on Surgical Outcomes in Peyronie's Disease: A Retrospective Cohort Study (AUA 2026) - No abstract available

Retrospective data

Current evidence on non-surgical therapies for Dupuytren's disease: A clinical review. (PubMed, J Hand Microsurg) - "Collagenase Clostridium histolyticum (CCH) injections have demonstrated rapid functional recovery and acceptable safety, although recurrence rates remain higher than those of open surgery...Consequently, therapeutic decisions must be individualized, taking into account disease stage, anatomical involvement, patient expectations, risk tolerance, and clinician expertise. Continued research is needed to refine patient selection criteria, optimize treatment combinations, and evaluate emerging molecular therapies targeting the disease's underlying pathobiology."

Journal • Review • Diabetes • Metabolic Disorders

Analysis of Last-line Treatments for Dupuytren's Contracture (AAOS 2026) - "This study's purpose is to examine the relationship of Dupuytren's treatment success and the last-line treatments of surgery, Xiaflex injection, steroid injection, or radiation to determine which treatment performs better... This study did not find evidence of a statistically significant difference (p=0.5582) between last-line treatments on chances of success. Therefore, we fail to reject the null hypothesis that the last-line treatment has no effect on the chances of success. Even though the success rates of surgery and radiation were very similar it must be noted that radiation is completely non-invasive."

Characterization of Tissue Histology for Collagenase Clostridium Histolyticum-aaes: Results in Human Following Abdominoplasty - An Exploratory Pilot Study. (PubMed, Aesthet Surg J) - "CCH-aaes induces localized subcutaneous remodeling without dermal disruption. The 3-aliquot technique elicits more robust histologic effects but increases bruising risk, while the grid method offers a more diffuse, potentially safer alternative. These findings clarify the tissue-level mechanism of CCH-aaes and may guide safer clinical use should the product return to market."

Journal • Aesthetic Medicine

Assessing the Impact of Collagenase Clostridium histolyticum Injection on Biomechanical Properties of Uterine Fibroids and Adjacent Myometrial Tissue. (PubMed, Reprod Sci) - No abstract available

Journal • Gynecology • Solid Tumor • Uterine Leiomyoma • Women's Health

Treatment of Dupuytren Contracture Recurrence After Surgery With Collagenase Clostridium Histolyticum: A Retrospective Multicenter Series. (PubMed, J Hand Surg Glob Online) - "This retrospective analysis indicates that CCH treatment is an effective and well tolerated nonsurgical option for recurrent postsurgical contracture, with results comparable to patients without prior surgery. Therapeutic III."

Journal • Retrospective data

Office-based penile plication with ring block: a safe and effective alternative to operating room-based surgery. (PubMed, J Sex Med) - No abstract available

Journal

The impact of the "bent carrot": Google search trends on Peyronie's disease increased following the introduction of collagenase clostridium histolyticum advertisement campaign. (PubMed, J Sex Med) - No abstract available

Journal

Investigating Techniques to Reduce Flexor Tendon Rupture Risk During Manipulation for Dupuytren Contracture. (PubMed, J Hand Surg Glob Online) - "Collagenase clostridium histolyticum injection and manipulation for treatment of Dupuytren contracture has a small risk of flexor tendon rupture...This study found that combining wrist flexion and remaining finger extension during manipulation decreases the force required to extend the small finger, suggesting a decrease in stress seen by the flexor tendons during manipulation. Therapeutic IV."

Journal • Fatigue

Concurrent Low Intensity Shockwave Therapy on Collagenase Clostridium Histolyticum for Peyronie's Disease (clinicaltrials.gov) - P=N/A | N=60 | Recruiting | Sponsor: Mayo Clinic | Trial completion date: Dec 2025 ➔ Jan 2027 | Trial primary completion date: Dec 2025 ➔ Dec 2026

Trial completion date • Trial primary completion date • Erectile Dysfunction

Retraction: In Vitro Study of Novel Collagenase (XIAFLEX®) on Dupuytren's Disease Fibroblasts Displays Unique Drug Related Properties. (PubMed, PLoS One) - No abstract available

Journal • Preclinical

Effectiveness of hyaluronic acid in the treatment of Peyronie's disease in the light of the European Urology Guidelines: the real-world experience. (PubMed, Minerva Urol Nephrol) - "Intralesional HA injections are safe and effective in improving patient's reported symptoms and subsequently quality of life in PD patients. This therapy may represent a valuable alternative in real-world clinical practice, especially in Europe where other pharmacological options are lacking."

Journal • Real-world evidence • Fibrosis • Pain • Urology

Nationwide Medicare and Medicaid Trends in Management of Dupuytren's Contracture. (PubMed, Hand (N Y)) - "Unlike international trends, US collagenase use continued to rise through 2022. Open fasciectomy remained primary, with a shift toward minimally invasive treatments and outpatient settings. Hand specialists are increasingly involved, though orthopedic surgeons lead in volume. These findings reflect evolving care models and highlight the need for continued monitoring of provider patterns and access to DC treatment."

Journal • Medicare • Reimbursement • US reimbursement • Orthopedics